World's seventh largest pharmaceutical company GlaxoSmithKline on Friday agreed to buy the HIV drug development assets from Bristol-Myers Squibb in a $1.4 billion deal. As per the deal, GlaxoSmithKline's HIV business, ViiV Healthcare will acquire operations specialising in early phase medicines and late stage treatments. Notably, ViiV is currently the second-largest HIV business by market share.